Depo-Provera Brain Tumor Lawsuit: August 2026 Status, Settlement Program, and What Women Need to Know

Last updated: August 17, 2026

The Depo-Provera meningioma litigation has entered a new phase. After months of building case counts and completing the pretrial groundwork, plaintiffs’ and defense leadership reached a settlement agreement in principle in June 2026 — and on August 10, the court appointed BrownGreer as the official settlement administrator to begin processing claims. The litigation has moved from “intake and build” mode into active settlement infrastructure. If you used Depo-Provera for an extended period and were later diagnosed with an intracranial meningioma, what happens next matters more than ever.

What Is Depo-Provera and What Are the Allegations?

Depo-Provera is an injectable form of birth control containing medroxyprogesterone acetate, a synthetic progestin manufactured by Pfizer (through its subsidiary Upjohn). Administered every three months, it has been used by millions of American women since FDA approval in 1992.

The central allegation: long-term Depo-Provera use significantly increases the risk of developing an intracranial meningioma — a tumor that grows along the membranes covering the brain. While often classified as “benign,” these tumors cause serious harm when they press against the brain: chronic headaches, vision loss, hearing loss, seizures, cognitive damage, and in severe cases, death. Treatment typically requires brain surgery, stereotactic radiosurgery, or radiation therapy.

Plaintiffs allege Pfizer knew or should have known about this risk — citing French pharmacovigilance research that found elevated meningioma rates in women using injectable progestins — and failed to provide adequate warnings to U.S. patients and prescribing physicians even after European regulators acted.

August 2026 Litigation Status: What’s Changed

The Depo-Provera federal cases are consolidated into MDL No. 3140 — In Re: Depo-Provera (Medroxyprogesterone Acetate) Products Liability Litigation — before Judge M. Casey Rodgers in the Northern District of Florida.

Here is where the litigation stands as of August 2026:

• MDL case count: As of August 3, 2026, the MDL has 6,294 pending federal cases — plus 337 in Delaware, 132 in New York, 118 in California, and additional state court clusters in Minnesota (6,899 plaintiffs), Connecticut, and Illinois.
• June 2026 agreement in principle: Plaintiffs’ and defense leadership reached an agreement in principle that is expected to provide a substantial percentage of MDL plaintiffs an opportunity to resolve their claims. Specific compensation tiers, amounts, and eligibility thresholds remain confidential at this stage.
• BrownGreer appointed settlement administrator: On August 10, 2026, Judge Rodgers appointed BrownGreer — the largest mass tort settlement administrator in the country — to run the mechanics of the settlement program. BrownGreer will collect plaintiff information and medical records, determine eligibility, implement the allocation system, and coordinate payments.
• No public compensation amounts yet: Individual settlement payouts are not public. No reliable figures circulating online should be treated as confirmed. Your attorney will evaluate where your specific case sits once the claims process opens.
• Attorneys are still accepting new cases. Women who match the eligibility profile can still submit claims for evaluation; the claims process is not closed.

Who May Qualify for a Depo-Provera Lawsuit

Not every woman who has used Depo-Provera has a viable claim. The general eligibility profile for cases currently being evaluated looks like this:

• Extended use: Most attorneys screen for at least one year of use, with stronger cases involving five or more consecutive years. Longer exposure supports the general causation argument based on current science.
• Intracranial meningioma diagnosis: A confirmed diagnosis of an intracranial meningioma (via MRI, CT scan, or pathology) is the medical requirement. The tumor must be intracranial — spinal meningiomas are a separate question.
• Timing: The strongest cases involve a meningioma diagnosed during or after the period of Depo-Provera use, with a documented history of injections in the plaintiff’s medical records.
• No conflicting progestin history: Defense counsel will scrutinize other progestin-based medications in your history. Attorneys review full medication records during evaluation to assess this exposure.

One of the most misunderstood aspects of these cases is the statute of limitations. Most states run the clock from the date you knew — or reasonably should have known — that your meningioma was connected to Depo-Provera use. That standard is applied with less flexibility than most people expect. If you are in the eligibility window, getting a case evaluation now is the smart move regardless of where the settlement program stands.

What Damages May Be Available

Depo-Provera meningioma claims are serious personal injury cases. The types of compensable damages in these claims include:

• Medical expenses — brain surgery, radiosurgery, radiation therapy, neurology follow-up, rehabilitation, and long-term medication costs, which frequently run well into six figures
• Lost wages and earning capacity — income lost during treatment and recovery, plus career impact from ongoing neurological deficits
• Pain and suffering — the lived experience of a brain tumor diagnosis, surgical recovery, radiation, and permanent neurological changes
• Permanent impairment — cases involving lasting vision loss, hearing loss, or cognitive deficits carry higher valuations because the impact is lifelong

Settlement amounts in mass torts are typically tiered by injury severity, age at diagnosis, and documented usage. Because the Depo-Provera settlement terms are not yet public, individual payout projections are speculative. What attorneys can do right now is evaluate whether your case facts put you in a position to participate in the settlement program.

What to Do If You Think You Have a Claim

If you used Depo-Provera for an extended period and were diagnosed with an intracranial meningioma, three steps matter right now:

1. Get a case evaluation with an MDL-active attorney. The settlement program is being set up, not wrapping up. Attorneys who are already in the MDL, have submitted Plaintiff Fact Sheets, and know the docket will give you the most accurate read on your situation.
2. Gather your records. Prescription records showing Depo-Provera use (from your OB/GYN or GP), imaging or pathology reports confirming the meningioma diagnosis, and a timeline of when symptoms appeared. Attorneys assist with records retrieval, but having your own copies speeds the process.
3. Do not wait on the statute of limitations. The settlement program being active does not pause any filing deadline. If you are uncertain whether you are still in your jurisdiction’s limitations window, a free consultation will answer that question.

For broader context on how mass tort settlements and long-term personal injury claims work, our guide on how long a personal injury lawsuit takes explains the MDL process, bellwether timeline, and how individual claims move through a settlement program. For serious injury cases like these, our overview of catastrophic injury claims covers the scope of damages available when injuries are permanent. You can also review how personal injury attorney fees work in mass tort contingency cases — no upfront costs, fees paid from any recovery.

Legal Giant connects users with personal injury attorneys currently handling Depo-Provera MDL cases. Consultations are free with no obligation. Get a free Depo-Provera case evaluation.